Sara Szal MD
If you wonder if you have Polyendocrine Metabolic Ovarian Syndrome (PMOS, the new name for PCOS), this is the post for you: I’m giving you the labs you need to test for it. Bring this to your doctor. And if you’ve been diagnosed with PMOS and you are on metformin, the birth control pill, or a GLP-1, or you are standing in the pharmacy trying to decide between them, this is the conversation your doctor visit almost certainly skipped.
After receiving limited education about PCOS in my medical training, I spent years creating a novel approach to the screening, diagnosis, and holistic treatment of the condition.
I’ve written before about how I was taught to ask an oversimplified question after diagnosing PMOS/PCOS: whether you want to get pregnant. This post is the next in the series about what is driving your symptoms, the labs, what a full panel would show if anyone ran it, and what each of those three prescriptions costs you that nobody mentions before you start. (Read the last post about PMOS/PCOS right here.)
In short, that is what this post covers, in the order I use it in practice.
What I was taught in training: start with the prescription, and treat lifestyle as an afterthought if the visit runs long.
What I now understand: the order is the whole treatment plan: lifestyle first, then the labs that show which root cause is driving her numbers, then the prescription that fits.
For years, the visit skipped past that foundation and went straight to one question: metformin if she wanted to get pregnant, the birth control pill if she did not. A GLP-1 prescription is a third option in that same rotation now, usually offered with less explanation than the first two. It can restore ovulation in a woman who spent years being told she probably couldn’t get pregnant, and it can cost her a portion of her muscle on the way there. I have never once seen both of those facts said out loud in the same visit.
Since May of this year, the condition underneath all of it got a new name, which is a good place to start along with the labs and what to do from a precision medicine perspective.
In June 2026, PCOS was formally renamed polyendocrine metabolic ovarian syndrome, or PMOS, retiring a forty-year-old name that was never accurate: most women with the condition do not have ovarian cysts in the pathological sense, and the name fixed a whole-body metabolic condition to a single ultrasound finding a meaningful share of women with it never even show. [1,2]
I have covered the consensus process behind the rename, and everything the old name cost women in delayed diagnosis, elsewhere in this series. [3]
This is a whole-body, polyendocrine condition, and insulin dysfunction sits close to its center: as many as 88 percent of women with it show a measurable alteration in insulin metabolism, not a subgroup finding. [4] That is the mechanism this piece is actually about: what should happen to a woman’s treatment plan once insulin dysfunction, not her ovaries, is treated as the driver.
PMOS is the most common endocrine condition in women of reproductive age. Current guidance puts prevalence at 10 to 13 percent of women, and close to 6 percent of adolescent girls worldwide under criteria that exclude the ultrasound finding at that age. [5,6] Health system records capture only a sliver of that, 0.2 to 5.2 percent in the United States, against a population-screened prevalence running as high as nearly 20 percent, a gap that is undiagnosed women, not unaffected ones. [7]
In my obstetrician/gynecology practice over the past 25+ years, I diagnose PMOS/PCOS in 20 to 30 percent of my patients. That encompasses about 35,000 women.
Diagnosis itself has been a system failure, and I have covered why in depth elsewhere in this series: most women wait years and see multiple clinicians before anyone connects the dots. [8] This piece picks up where I left off with how I define menstrual irregularity, the lab panel I run, what should happen next, supplements, medications, and in what order.
The root causes underneath PMOS include insulin dysfunction, genetics, chronic stress, and environmental toxin exposure including mercury, lead, cadmium, and arsenic, are the subject of their own piece in this series. [9,10,11,12]
What matters for this piece is what should follow from them in a logical sequence. Every one of those root causes is addressable before or alongside a prescription, and none of them surface in a two-minute conversation about pregnancy intent.
Every one of the three prescriptions below sits on top of the same foundation: lifestyle management. Diet quality, movement, sleep, and stress regulation are recommended as first-line therapy for this condition regardless of body weight, and that recommendation is real, not a footnote before the prescription. [2] It also gets acknowledged in one sentence and skipped in practice, because a fifteen-minute visit has room for a prescription and rarely has room for a real conversation about how to change what someone eats or how they move. Nothing below replaces that foundation; it is what I reach for when the foundation alone has not been enough, or has not been given the time it needs to work.
None of the three are the problem. Metformin still earns its place as first-line therapy for the metabolic piece of this condition. [2] The birth control pill still works exactly as advertised on the luteinizing hormone surge driving excess androgen production. A GLP-1 adds a mechanism neither of the first two touches directly, outperforming metformin on weight, waist circumference, and insulin resistance markers in head-to-head trials, which explains how fast it has moved into this rotation. [13] Each one has a real job to do.
My own insulin resistance responded to food and movement changes before it ever needed a prescription, which is the pattern I look for before reaching for any of the three prescriptions mentioned above.
What I believe is wrong is not any one of these three prescriptions; it is the sequence, and now, with a third option in rotation, the sequence has gotten more complicated rather than less. Which women benefit from a GLP-1 in this condition. Which agent. What it costs a woman’s muscle, bone, and fertility timeline while it is doing its job. That conversation is happening in exam rooms across the country right now, and almost none of them include the information below.
Bottom line: GLP-1 receptor agonists move real numbers in this condition, weight, insulin resistance, even ovulation. They also carry a risk profile, a fertility risk almost no prescriber flags, and a sequencing question that the fifteen-minute visit handing out the prescription rarely covers.
The protocol below covers the risk profile almost no one discusses before the GLP-1 prescription is written: a 37 percent increase in gallbladder and biliary disease risk, a measurable loss of bone density, roughly a quarter to a third of the weight lost coming from muscle instead of fat, and the boxed warning worth understanding rather than dismissing.
It also covers the sequencing question underneath all of it: which root-cause phenotype from Section III predicts who benefits from a GLP-1, which agent fits which woman, and the precision lab panel I use to tell the difference before I write the prescription.
It also covers the lifestyle foundation underneath all three prescriptions, and the five supplements with real evidence behind them, inositol, probiotics, omega-3, vitamin D, and curcumin, plus a second tier worth knowing about even though the evidence is thinner.
And it covers the fact almost no prescriber raises before writing this prescription: a GLP-1 can restore ovulation in a woman who was told for years she probably could not get pregnant. If no one has talked to you about contraception since you started, keep reading.
